EntityRisk

How do we get to a future where patients’ needs are addressed efficiently and affordably, extracting the greatest possible benefit for society from the innovations scientists are working on today?    We hope to see you at Biofuture 2024 in NYC today, where Neal Masia will be discussing hard questions in health economics together with Peter L. Rubin, Nouhad Husseini, Philippe Lopes-Fernandes, Jennifer Hawks Bland, and Congressman Jake Auchincloss.     There will also be additional panels and multiple presentations focusing on hot topics including the impact of AI, quantum computing, bioethics and upcoming regulations on medical research.     Learn more, including how to access the recording online if you are unable to come in person, here: https://lnkd.in/gMr6GRNE    #HEOR #HealthEconomics #HealthcareReform #DrugPricing  #biofuture2024 

Catch our CSO Darius Lakdawalla this Saturday in Boston for the Celebrating Cost Effectiveness Analysis symposium hosted by the Center for the Evaluation of Value and Risk in Health (CEVR) (Tufts Medical Center) and Duke-Margolis Institute for Health Policy! He'll be joining distinguished health economists Anirban Basu, Melanie Whittington, and Beth Woods on the 4 PM panel, exploring promising new approaches to cost-effectiveness analysis in healthcare. You won’t want to miss these panel discussions. To tune in virtually, register here: https://lnkd.in/gEQSsdH6 #HEOR #Innovation #DrugPricing #BioPharma #HealthEconomics

A team of scientists from EntityRisk and Pfizer were highlighted in ISPOR—The Professional Society for Health Economics and Outcomes Research’s Value and Outcomes Spotlight.   “For new medicines, and even many established ones, evidence of effectiveness rests primarily on data from a pivotal clinical trial designed for regulatory approval. Yet, in nearly all cases, clinical trial participants differ significantly from real-world patients who use the drug,“ Devin Incerti, Andrew Morris, Joe Cappelleri, Valeria Merla, MPH, Nathaniel Posner, Dana P Goldman, and Darius Lakdawalla write.   EntityRisk has produced software that implements cutting-edge machine-learning methods for predicting real-world benefits of pipeline medicines. Instead of choosing between real-world estimates and randomized trial estimates, Bayesian machine-learning methods allow both to be inputs into a robust prediction algorithm that yields unbiased estimates and accurate measures of uncertainty.   Read the full article here: https://lnkd.in/gGXedpUg   #RWE #HEOR #DrugPricing #BioPharma #HealthEconomics

Join us at the Biofuture 2024 conference in New York City on October 28! Neal Masia will join the Tackling the Hard Questions panel together with Peter L. Rubin, Nouhad Husseini, Philippe Lopes-Fernandes, Jennifer Hawks Bland and Congressman Jake Auchincloss. If you are looking to navigate the changes underway in healthcare and health economics, you will want to attend. We’re a proud sponsor. Drop us a line if you will be there! Register here: www.biofuture.com #HEOR #HealthEconomics #HealthcareReform #DrugPricing  #biofuture2024 

The Congressional Budget Office is revising the costs of the IRA by up to $20 billion, focusing on Medicare Part D for next year. “After accounting for information about 2025 bids from plans that provide coverage under Part D, CBO expects that the additional plan costs reflected in those bids will result in an increase in federal spending of $10 billion to $20 billion in calendar year 2025, compared with our earlier projections,” CBO’s letter addressed to several prominent members of Congress reads. “CBO also estimates that the temporary subsidies will increase federal spending in calendar year 2025 by an additional $5 billion and that, over the next decade, this will lead to an increase of $2 billion in net spending for interest, relative to prior projections.” How do you map those changes to a new therapy's prospects? Drop us a line to learn more. Read the full letter here: https://lnkd.in/gyjrT3Sn #HEOR #DrugPricing #BioPharma #HealthEconomics #IRA 

"Generative AI is transforming drug discovery by allowing us to build sophisticated models and seamlessly integrate AI into the antibody design process,” David Reese, Executive VP and CTO of Amgen, told AI Business in March as NVIDIA launched its own digital toolkit. “Our team is harnessing this technology to create the next generation of medicines that will bring the most value to patients.” (https://lnkd.in/gCS94Wnj) AI/ML tools are proliferating. What will the impact be on the value of current and future therapies, and how will those tools actually know what brings the most value to patients? It's hard to know unless you have a flexible approach to value assessment that can accommodate multiple stakeholder value frameworks. Our PROVEN™ advanced digital platform helps biotech innovators and investors model uncertainty in value with unprecedented accuracy and flexibility. Reach out to learn more! #AI #HEOR #BioPharma #HealthEconomics #DataScience

Exciting team news! Our Head of Client Success Dana Panzer is taking over as VP of Operations. Dana’s business acumen and her intimate knowledge of our operations are assets that will help us pursue the next stages of our business plan as we expand to help our clients better navigate the stormy waters of today’s biopharma environment. Congratulations, Dana! #Biotech #Pharma #ClientSuccess #HealthEconomics #HEOR

We are excited to have Eleanor (Ellie) Crecelius back with us as Manager of Client Success!  We are looking forward to her skill with clients adopting our cutting-edge PROVEN ™ platform and the expansion of our consulting services to help more investors and biotech companies accurately model the value of the therapies in their pipeline in these tumultuous times for the industry. #Biotech #Pharma #ClientSuccess #HealthEconomics #HEOR 

USC Schaeffer Center for Health Policy & Economics highlights that three PBMs account for 80% of prescriptions in the United States. But there has been limited information about how PBM concentration varies across payer types. The team at USC found all three payer markets exceeded a U.S. Department of Justice threshold for “highly concentrated” based on the commonly used Herfindahl-Hirschman Index. The Part D market had the highest level of concentration, while commercial insurance had the lowest. See the full report for what else they found. “These findings underscore the importance of considering payer-specific concentration when evaluating PBMs’ anti-competitive practices, as the 3 top PBMs may be pursuing different market strategies,” researchers Dima Mazen Qato, Yugen Chen and Karen Van Nuys in JAMA. The findings could inform proposed legislation aimed at reforming PBM practices and the Federal Trade Commission’s ongoing investigation into PBMs. #DrugPrices

We are thrilled to welcome Alison Ruderian to our team as Vice President of Data Insights!  Alison brings a decade of experience in health economics and research, having most recently served as Real World Data and Solutions Director at Inovalon Insights. Her meticulous attention to detail and ability to extract clear patterns from complex data sets make her an invaluable asset for us at a time of rapid expansion and exciting challenges and opportunities.  We can’t wait to work together! #NewHire #data #DrugPricing #Biotech #Pharma